《盈警響號》新銳醫藥(06108.HK)料去年錄虧損 聯營公司減值約2,100萬元
新銳醫藥(06108.HK)公布,集團預計截至去年12月31日止財政年度將錄得虧損,主要源於營業額及毛利大幅減少,主要由於年度產品的生產及銷售暫停導致產品銷售下降;年度並無錄得視作出售WinHealth International權益所得收益淨額;及自集團分別於2018年4月及10月配發及發行WinHealth International的新股份予其他各方,導致其於WinHealth International所擁有權益被攤薄後,集團對WinHealth International的投資自2018年10月起已不再分類為聯營公司權益,因此導致年度分佔聯營公司溢利減少。
集團指,預期於去年12月31日就該聯營公司權益確認之減值虧損將約為2,100萬元,而2018財政年度則並無相關減值虧損。此外,預期集團將就集團於年度的貿易及其他應收款項錄得預期信貸虧損撥備約900萬元,而2018財政年度並無相關信貸虧損撥備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.